Kyverna Therapeutics KYTX
NASDAQ KYTX
$5.12 +0.04 (+0.79%)
At close: Nov 11, 2026 · 4:00 PM EST

Kyverna Therapeutics (KYTX) Net Income Attributable to Noncontrolling Interests (2023 - 2024)

Updated

Analysis

Kyverna Therapeutics (KYTX) Net Income Attributable to Noncontrolling Interests (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Kyverna Therapeutics 312.78 Mn -573.60 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -48,000.00
Sep 30, 2024 190,000.00
Dec 31, 2023 -1,000.00
Sep 30, 2023 5,000.00
API Access

Kyverna Therapeutics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=KYTX&period=max&api_key=YOUR_API_KEY